Exhibit 9

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Center for Devices and
Radiological Health
2098 Gaither Road
Rockville, MD 20850

FEB 27 2003

Mr. Lynn Satterthwaite
Vice President and General Manager
Computerized Thermal Imaging, Incorporated
1719 West 2800 South
Ogden, Utah 84401

Dear Mr. Satterthwaite:

The purpose of this letter is to acknowledge receipt of your letter dated December 19, 2002, and your facsimile dated January 10, 2003, addressed to Mr. Kevin Hopson. You responded to the Form FDA-483, "Inspectional Observations," that was issued by Ms. Linda M. Cherry at the close of the inspection of your establishment as the sponsor of the Computerized Thermal Imaging Breast Cancer System Model 2100 and to augment your response to the second FDA-483 observation at Mr. Hopson's request. Ms. Cherry, an investigator with FDA Denver District Office, conducted the inspection on September 16-24, 2002.

Implementation of the corrective actions noted in your letter regarding study monitoring should assist you in avoiding recurrence of the problems noted during the last inspection. Although you are unable to provide the written informed consent of Subject SA0444, you were able to provide us with documentation in the facsimile to substantiate the likelihood of consent from the subject.

The clinical site should make it a standard practice to provide a copy of the written consent to the subjects so they may contact those persons associated with the study about their concerns with the research and their rights in the study. Your documentation indicates that the clinical site was unsure whether the subject received a copy of the informed consent.

In future clinical investigations, we request that you implement appropriate measures to ensure participating subjects receive a copy of their signed consent and that clinical investigators participating in these studies maintain a copy of the informed consent in the subject's records. As a sponsor, you are responsible for securing compliance in your clinical investigation. Clinical investigators are responsible for the accuracy and completeness of the study records and for any discrepancies found in their records.

We appreciate the courtesy and cooperation extended to Ms. Cherry during the inspection. No response to this letter is necessary.

Your corrective actions may be verified during a future inspection. If you have any questions, please feel free to contact Mr. Hopson at (301) 594-4720, extension 128 or by facsimile at (301) 594-4731.

Sincerely yours,



David R. Kalins
Chief, Program Enforcement Branch I
Division of Bioresearch Monitoring
Office of Compliance
Center for Devices and Radiological Health